Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from Viracta Therapeutics ( (VIRX) ) is now available.
Viracta Therapeutics, a clinical-stage precision oncology company, is prioritizing its Nana-val development program for treating relapsed Epstein-Barr virus-positive lymphoma by cutting 42% of its workforce and reducing its Board of Directors from ten to six members. This strategic move is aimed at conserving resources and streamlining operations while advancing the Nana-val program towards a potential New Drug Application submission. The reshaping of the company reflects a focused effort to align resources with pipeline priorities, ensuring the company’s sustainability and future growth.
See more data about VIRX stock on TipRanks’ Stock Analysis page.
